Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain

Josep M Llibre1,2, Gloria Cardona3, José R Santos3, Angès Andreu3, Josep O Estrada4, Jordi Ara4, Xavier Bonafont3, Bonaventura Clotet1,2

1HIV Unit, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; 2Lluita contra la SIDA Foundation, Badalona, Barcelona, Spain; 3Hospital Pharmacy, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; 4Hospital Management, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Background: The current economic recession in European countries has forced governments to design emergency measures to reduce spending on drugs, including antiretroviral therapy (ART). Switching antiretroviral drugs for others that have the same efficacy and safety profile at a lower cost (cost-reduction measures, CRM) could prove to be a valid means of generating savings.

Methods: Descriptive study of prospective consensus-based CRM undertaken in 2011 in a Catalonian hospital HIV unit among patients with prolonged plasma HIV-1 RNA <50 copies/mL.

Results: During the study period, we made 673 switches (87.5% more than the previous year), of which 378 (56.2%) were CRM (16% of all patients treated), leading to a savings of €87,410/ month. Switching tenofovir/emtricitabine for abacavir/lamivudine was the most common CRM (129, 31.3%), followed by simplification to boosted protease inhibitor monotherapy (bPImono, 102, 26%). The CRM that generated the greatest saving were switching to bPImono (38%), withdrawal or replacement of raltegravir (24%), switching tenofovir/emtricitabine for abacavir/lamivudine (13%), and switching to nevirapine (5%). Cost savings with CRM were slightly higher than those achieved with medication paid for by clinical trial sponsors (€80,333/month) or through discount arrangements (€76,389/month).

Conclusion: Proactively switching antiretroviral therapy in selected treated patients with sustained virological suppression can generate significant cost savings in pharmacy spending in developed countries. These findings have implications for decision makers in designing safe strategies that maintain HIV-1 suppression at lower costs.

Keywords: health economics, cost analysis, antiretroviral agents economics, antiretroviral therapy highly active, protease inhibitor monotherapy

Introduction

The economic recession that began in 2008 has brought to light a series of structural problems in some European economies. Public debt has reached unprecedented levels that have jeopardized the sustainability of public finances and called into question the functioning of the economic systems of Greece, Ireland, Portugal, Spain, and Italy.1 Recessions have significant adverse effects on health and health care.2 Public financing of the national health system has been severely restricted in order to maintain universal access to public health care.3,3 Medication costs are the second largest component of public health spending in Spain, and hospital medication costs account for 36.5% of total spending on drugs.3 Expenditure on medication in Spanish hospitals increased by 55% in 4 years, from
€3.7 billion in 2006 to almost €5.8 billion in 2010. More than 60% of this expense is from outpatient drugs, which must be prescribed by a hospital doctor, require special follow-up, and can only be dispensed by hospital pharmacy services. They include mainly antiretroviral drugs, cytostatic drugs, anti-TNF agents, interferon, erythropoietin, and antiviral agents that act directly against hepatitis C infection. The high price of these drugs is a key cause of the increase in total hospital expenditure, since cytostatic and antiretroviral drugs account for more than half of all spending on these products.

Spain’s hospital expenditure on drugs has reached a peak of €6,369,300,000, which was the debt to pharmaceutical companies in December 2011; that is 36% higher than the debt remaining at the end of 2010. The mean delay in payments from the National Health Service to the pharmaceutical industry in 2011 was 525 days, 135 more than in 2010 (annual increase of 34.6%).

Consequently, the government designed a series of emergency measures to reduce overall hospital spending by 11% in order to maintain the immediate sustainability of the health system. Clinicians at care of HIV were encouraged to accomplish the goals. These measures are based on promoting the use of generics, reducing the cost of outpatient drugs, and encouraging cost-effectiveness criteria.

We describe the measures adopted with respect to prescription of antiretroviral drugs in a hospital HIV unit within the setting of a severe economic recession in order to reduce the cost of antiretroviral therapy (ART) in the immediate short term. We compare the impact of the savings achieved with that of other measures to reduce spending on ART.

Methods and setting

We made a descriptive analysis of prospective data from the HIV unit of a 638-bed hospital (Hospital Universitario Germans Trias i Pujol, Barcelona, Spain). The unit comprises a team of 14 prescribing specialists attending 2577 patients from clinical trials or advanced salvage regimens; usually from 600 mg/100 mg twice daily to 800 mg/100 mg once daily.

study, a switch in ART is defined as any of the following: prescription of any antiretroviral agent that differs in dose or frequency from that of the previous month, switching one of the drugs in the regimen with respect to the previous month, initiation or reinitiation of ART after >1 year of discontinuation, and entry to or conclusion of a clinical trial with partial or total payment of ART by the sponsor.

Cost-reduction measures (CRM) include all those switches that aim to reduce the cost of treatment in patients with virological suppression (defined as plasma HIV-1 RNA <50 copies/mL).

Definition of criteria for switching ART

Members of the medical team agreed upon the categories of CRM and treatment regimens that did not compromise the safety and efficacy profiles of previous regimens. In addition, physicians were able to initiate any of the agreed regimens or prescribe other regimens according to their individual criteria. Physicians’ criteria were consistent with those of national and European ART clinical practice guidelines. Trained psychologists in the HIV Unit provided psychological support in order to ensure good adherence. Table 1 shows all the CRM used in this study. In the switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), patients had to be negative for HBsAg and HLA-B*5701. Switches from triple ART to monotherapy with darunavir/ritonavir (DRV/r once daily [QD]) or lopinavir/r (LPV/r two times daily [BID]) were made in patients with no history of virological
failure, HIV-1-RNA <50 copies/mL for at least 6 months before switching, good adherence to ART, and a nadir CD4 >100 cells/mm³. Raltegravir (RAL), etravirine (ETR), or maraviroc (MVC) was suspended mainly in patients who had initiated the drug in a previous clinical trial or those receiving salvage regimens with a further 3 active drugs after a prior virological failure; when necessary, RAL, ETR, or MVC was switched for another completely active drug.

Data were recorded by consulting the electronic antiretroviral dispensation system of the hospital pharmacy service. The only costs included in the analysis were those of the antiretroviral combinations analyzed, since the analysis was performed from the point of view of pharmacy spending. Cost was based on the price to retailer in Euros for the year 2011 plus taxes in Spain (4% VAT) according to the antiretroviral treatment guide of GESIDA/Spanish Secretariat for the National Plan on AIDS.¹²

For each switch in ART, the hospital pharmacist recorded the patient’s data, date of switch, reason for switch, previous ART, and new ART. When the new regimen was more economical than the previous one, the patient’s electronic clinical history was consulted to rule out clinical indications for the switch (toxicity, virological failure, drug interactions, pregnancy, and entry to or conclusion of a clinical trial with partial or total payment for medication by the trial sponsor). In cases where no clinical justification was apparent, the measure was considered a CRM. A second revision by a physician from the HIV unit served to validate the classification.

In order to calculate the monthly saving of each CRM, the monthly cost of the new ART was subtracted from the monthly cost of the previous ART, and the result was assigned to the category of switch it belonged to (Table 1). In cases where two CRMs coincided in a switch, 50% of the monthly saving was assigned to each category. For example, the switch from RAL + TDF/FTC to DRV/r was considered both a change from RAL to a more economical drug and initiation of monotherapy with DRV/r.

### Calculation of other CRMs

During the same period, we also counted the number of patients who were in a clinical trial whose sponsor financed all or part of ART, as well as the saving achieved with discount arrangements.

### Results

During the study period, 673 of the 2401 patients treated (28.02%) received a switch of ART, that is, an increase of 87.46% with respect to the 359 switches made during the same period the previous year, which was considered the control period.

Of the 673 switches, 378 (56.17%) were due to CRM. The second most numerous group of changes were those made because of toxicity (11.29%), followed by initiation/reinitiation of therapy (9.51%) and switches due to virological failure (6.54%). The economic impact of each of these types of change is shown in Table 2. The total number of CRM represented a savings of €87,409.80/month in pharmacy spending during the study period.

If we analyze the type of CRM, we see that 421 were adopted for the 378 switches in treatment. The percentage for each CRM according to the number of times it was applied is shown in Figure 1 and Table 3. The switch from TDF/FTC to ABC/3TC was the most common (129 times, 30.64%): it was made as the only switch on 98/129 occasions, and combined with another CRM on 31/129 occasions. The second most common CRM was simplification to monotherapy with DRV/r (63, 14.96%) and with LPV/r (41, 9.74%). In contrast, the cost savings achieved show that the CRM that generated the greatest saving was simplification to monotherapy with boosted protease inhibitors (PIs)/r). Switches to monotherapy with DRV/r accounted for 22.7% of the total saving; switches to LPV/r accounted for 15.01%. The five most efficient types of CRM (switches to monotherapy with DRV/r or LPV/r, switches from TDF/FTC to ABC/3TC, discontinuations or replacements of RAL, and switches to NVP) account for

<table>
<thead>
<tr>
<th>Treatment change goal</th>
<th>Monthly cost (€)</th>
<th>N</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost-saving measures</td>
<td>–87,409.80</td>
<td>378</td>
<td>56.17%</td>
</tr>
<tr>
<td>Toxicity</td>
<td>12,022.50</td>
<td>76</td>
<td>11.29%</td>
</tr>
<tr>
<td>Treatment-naive patients initiating ART, patients receiving treatment in the center for the first time, or reinitiation of ART &gt;1 year after withdrawal*</td>
<td>52,995.60</td>
<td>64</td>
<td>9.51%</td>
</tr>
<tr>
<td>Inclusion in clinical trials*</td>
<td>–2712.00</td>
<td>47</td>
<td>6.83%</td>
</tr>
<tr>
<td>Virological failure</td>
<td>17,657.85</td>
<td>44</td>
<td>6.54%</td>
</tr>
<tr>
<td>Others</td>
<td>8100.00</td>
<td>31</td>
<td>4.61%</td>
</tr>
<tr>
<td>Postexposure prophylaxis</td>
<td>16,710.00</td>
<td>22</td>
<td>3.27%</td>
</tr>
<tr>
<td>Ends a clinical trial*</td>
<td>3826.80</td>
<td>9</td>
<td>1.34%</td>
</tr>
<tr>
<td>Toxicity plus adherence or pharmacokinetic issues</td>
<td>1406.70</td>
<td>2</td>
<td>0.30%</td>
</tr>
<tr>
<td>Total</td>
<td>30,962.85</td>
<td>673</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

*Notes: *Reinitiation <1 year after withdrawal was not included because it was not considered a change in treatment; *only clinical trials in which the sponsor paid for any part of the antiretroviral treatment are included.

Abbreviation: ART, antiretroviral treatment.
### Table 3: Comparison of the number of cost-reduction measures undertaken (shown as categories) and costs saved with each one

<table>
<thead>
<tr>
<th>Category of antiretroviral cost-reduction measure</th>
<th>N changes</th>
<th>Percentage of changes</th>
<th>€/month saved</th>
<th>Percentage of costs saved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darunavir/ritonavir monotherapy</td>
<td>63</td>
<td>14.96%</td>
<td>19,845.15</td>
<td>22.70%</td>
</tr>
<tr>
<td>Lopinavir/ritonavir monotherapy</td>
<td>41</td>
<td>9.74%</td>
<td>13,122.00</td>
<td>15.01%</td>
</tr>
<tr>
<td>Withdrawal of raltegravir</td>
<td>23</td>
<td>5.46%</td>
<td>12,718.50</td>
<td>14.55%</td>
</tr>
<tr>
<td>TDF/FTC to ABC/3TC</td>
<td>129</td>
<td>30.64%</td>
<td>10,977.15</td>
<td>12.56%</td>
</tr>
<tr>
<td>Substitution of raltegravir</td>
<td>32</td>
<td>7.60%</td>
<td>7,582.95</td>
<td>8.68%</td>
</tr>
<tr>
<td>Switch to nevirapine</td>
<td>33</td>
<td>7.84%</td>
<td>4,135.50</td>
<td>4.73%</td>
</tr>
<tr>
<td>Withdrawal of etravirine</td>
<td>9</td>
<td>2.14%</td>
<td>3,518.40</td>
<td>4.03%</td>
</tr>
<tr>
<td>Reduction of dose of darunavir</td>
<td>20</td>
<td>4.75%</td>
<td>3,355.50</td>
<td>3.84%</td>
</tr>
<tr>
<td>Withdrawal of maraviroc</td>
<td>4</td>
<td>0.95%</td>
<td>2,486.70</td>
<td>2.84%</td>
</tr>
<tr>
<td>Withdrawal of inactive NRTI</td>
<td>5</td>
<td>1.19%</td>
<td>1,947.90</td>
<td>2.23%</td>
</tr>
<tr>
<td>Switch to EFV/TDF/FTC</td>
<td>10</td>
<td>2.38%</td>
<td>1,878.00</td>
<td>2.15%</td>
</tr>
<tr>
<td>Reduction of dose of maraviroc</td>
<td>7</td>
<td>1.66%</td>
<td>1,518.15</td>
<td>1.74%</td>
</tr>
<tr>
<td>Other</td>
<td>6</td>
<td>1.43%</td>
<td>1,324.20</td>
<td>1.51%</td>
</tr>
<tr>
<td>Lamivudine generic (break FDC)</td>
<td>15</td>
<td>3.56%</td>
<td>1,111.20</td>
<td>1.27%</td>
</tr>
<tr>
<td>Withdrawal of tipranavir</td>
<td>4</td>
<td>0.95%</td>
<td>639.90</td>
<td>0.73%</td>
</tr>
<tr>
<td>Reduction of dose of fosamprenavir</td>
<td>4</td>
<td>0.95%</td>
<td>559.80</td>
<td>0.64%</td>
</tr>
<tr>
<td>ATV/ritonavir to unboosted ATV</td>
<td>14</td>
<td>3.33%</td>
<td>481.80</td>
<td>0.52%</td>
</tr>
<tr>
<td>Substitution of etravirine</td>
<td>2</td>
<td>0.47%</td>
<td>237.00</td>
<td>0.27%</td>
</tr>
<tr>
<td>Total</td>
<td>421</td>
<td>100.00%</td>
<td>87,409.80</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

**Abbreviations:** ABC/3TC, abacavir/lamivudine; ATV, atazanavir; DRV/r, darunavir/ritonavir; EFV, efavirenz; ETR, etravirine; FDC, fixed-dose combinations; FPV, fosamprenavir; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; RAL, raltegravir; TDF/FTC, tenofovir/emtricitabine; TPV, tipranavir; 3TC gen, generic lamivudine.

**Figure 1** Correlation between the number of switches identified as cost-saving measures and the costs saved with them (shown as percentages).

**Abbreviations:** ABC/3TC, abacavir/lamivudine; ATV, atazanavir; DRV/r, darunavir/ritonavir; EFV, efavirenz; ETR, etravirine; FDC, fixed-dose combinations; FPV, fosamprenavir; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; RAL, raltegravir; TDF/FTC, tenofovir/emtricitabine; TPV, tipranavir; 3TC gen, generic lamivudine.
78.23% of the saving achieved. The most frequent switch (TDF/FTC to ABC/3TC) only generated the fourth largest saving. The correlation between the number of CRM adopted and the savings achieved with each category of switch is shown in Figure 1.

During the same period, we identified 117 patients who participated in clinical trials with medication that was totally or partially paid for by the sponsor. This category generated a saving of €80,332.87/month.

The reduction in the purchase costs of antiretroviral drugs through discount arrangements generated a saving of €76,389.40/month during the same period (Figure 2).

At 48 weeks, 318 (84.1%) patients remained with the same CRM regimen. Only eight (2.1%) subjects developed virological failure (a confirmed plasma HIV-1 RNA >50 copies/mL), and the treatment was changed due to drug-related adverse events (all of them grade 1 or 2) in 26 (6.9%) subjects.

Discussion
In a severe economic recession with a direct impact on hospital pharmacy budgets in developed countries with free access to ART, switches aimed at reducing the cost of antiretroviral treatment agreed upon by the medical team of a hospital HIV unit led to a significant saving in total cost of therapy. These CRM led to savings similar to or higher than those achieved through clinical trials with antiretroviral medication paid for in total or in part by the sponsor. Likewise, the saving was slightly higher than that achieved through the discount arrangements in force during the same period.

The number of switches in ART during this period was almost double (+87.5%) that for the same period the previous year; more than half (56.2%) were CRM, thus highlighting the involvement of prescribing physicians from the HIV unit in achieving the priority objective of reducing the cost of ART in the immediate short term. Overall, 16% of patients treated received a change in CRM in their ART, generating a savings of €87,409.80/month in the purchase of antiretrovirals.

The most frequent CRM were switches in NRTI combinations from TDF/FTC to ABC/3TC, switches to monotherapy with PI/r (DRV or LPV), switches to NVP, and withdrawals or replacements of RAL.

In contrast, the CRM that generated the greatest savings were switches to monotherapy with PI/r (DRV or LPV, slightly more than one-third of the total saving achieved), suspension of RAL in patients with sustained virologic suppression after receiving a salvage regimen, replacement of RAL by another active drug, replacement of TDF/FTC by ABC/3TC, switches to NVP, and suspension of ETR in patients who had received salvage regimens. All of the above CRM accounted for almost 90% of the total saving achieved.

The results are consistent with mathematical models of potential cost savings generated with DRV/r in monotherapy. The models assumed that 15%–40% of treated patients with virological suppression would be candidates for DRV/r monotherapy. In our series, 4.2% (103 of 2401) of patients treated switched to PI/r monotherapy during the study period. Therefore, although switches to PI/r in monotherapy were important CRM, they only generated one-third of the total savings; the remaining CRM play an equally important role in achieving cost saving objectives.

The cost of antiretroviral drugs (approximately €7250/patient/year) remains the major factor contributing to treatment and care costs. As HIV disease is treated earlier with more efficacious drugs, survival – and therefore costs of care – will continue to increase. Most patients treated in developed countries have complete virological suppression. It is necessary to find ways to lower the costs of HIV care while maintaining the highest medical standards. In Spain, ART is prescribed in reference hospital-based HIV units, thus facilitating implementation of CRM. Physicians prescribing ART should be aware that more economical options, along with equal efficacy and tolerability, may be available. They must have the full support of their hospital managers to preserve the efficacy and safety. Such cooperation would alleviate some of the conflicts involved when faced with the need to rationalize spending.

Individual components of the ART combination regimen are frequently switched for several reasons, including
management of antiretroviral drug toxicity or intolerance, desire for once-daily dosing and reduced pill burden, management of potential drug interactions, patient preference, and cost. 11,21,22 National and international ART guidelines give increasing importance to cost-effectiveness criteria for prescription of ART. 12,16–18 Furthermore, earlier initiation or even universal prescription of ART to all HIV-1-infected patients increases national expenditure on ART everywhere, with the result that cost savings are increasingly relevant. 9,17,19–21 Consequently, reducing the cost of ART is an immense challenge to managers and administrators at both local and national level, health care professionals, the pharmaceutical industry, and patients, particularly now that the HPTN 052 trial has proved that “treatment as prevention” works. 22,23 It is increasingly clear that highly active antiretroviral therapy is not only a life-saving approach, but also an effective means of preventing transmission of HIV. A collaborative approach is thus required, as this target will not be reached without the profound commitment of prescribing physicians. Prescription of generics and implementation of CRM seem to be the preferred strategies for reaching this objective and maintaining free access to the health system and ART. 11,18,21

The potential reduction in costs using CRM is not indefinite, as once most of the CRM for switching ART are in place, no further cost reductions are possible with new CRM, and the strategy can only be used for maintenance. Therefore, other cost-saving strategies must be evaluated, especially price controls and replacement of brand name drugs or regimens with generics. 9–11,18,24

The immediate need for cost savings in our setting prevented the performance of a prospective clinical trial to evaluate the full economic impact of the strategy, including all direct and indirect costs, and the possibility of confirming whether or not the measures were really cost-effective. The cost of potential toxicity or treatment failures resulting from these measures should be monitored in order to evaluate their impact on the final cost savings. In addition, the durability of switches should be analyzed. Such a study is already under way in our center; however, based on data from 2006 and earlier, ART already represented approximately 70% of the cost of health care in HIV-infected patients in Spain; undoubtedly, this percentage has increased owing to the continued reduction in morbidity and mortality in HIV-infected patients in developed countries. 9,25 Therefore, it seems highly unlikely that these CRM will not prove to be cost-effective; however, a cost-effectiveness analysis is mandatory to confirm this hypothesis.

We did not analyze switches to more expensive ART regimens made during the study, as these were not considered CRM. In some cases, a more economical ART regimen might have been chosen; therefore, such switches could have the potential for further savings, but they were not evaluated in the present series.

In conclusion, our findings suggest that switching ART could generate significant cost savings during a severe economic recession. The main strategies for reducing the cost of ART and guaranteeing free health care in developed countries in recession are as follows: CRM combined with prescription of generic drugs, savings from clinical trials in which the sponsor pays for treatment, and savings generated by discount arrangements. The cost-effectiveness of CRM should be thoroughly evaluated by including direct and indirect costs. Similarly, strategies that involve prescribing physicians in cost savings in ART should be developed. Finally, patients who are candidates for CRM should be identified using strict inclusion criteria to ensure adequate safety and efficacy and taking the relevant ethical conditions into account.

**Acknowledgments**

This work was supported by CHAIN, Collaborative HIV and Anti-HIV Drug Resistance Network (Integrated Project no 223131, funded by the European Commission Framework 7 Program) and by Gala contra la Sida. Barcelona 2011. We are grateful to Thomas O’Boyle for editorial assistance.

**Disclosure**

Josep M Llibre has received funding for research or payment for conferences or participation on advisory boards from Abbott, Boehringer-Ingelheim, Bristol–Myers Squibb, Gilead Sciences, Jansen-Cilag, Merck Sharp and Dohme, Tibotec, and ViiV Healthcare. José R Santos has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Janssen-Cilag, Bristol–Myers Squibb, ViiV Healthcare, and Pfizer. Bonaventura Clotet has served during the past 2 years as a consultant on advisory boards or participated in speakers’ bureaus or conducted clinical trials for BMS, Abbott, Gilead, Janssen, Merck, Siemens, and ViiV. Xavier Bonafont has received payment for conferences from Abbott and Gilead Sciences. Angels Andreu has received payment for conferences from Abbott and Janssen-Cilag.
The other authors report no conflicts of interest in this work.

References